|Bid||117.55 x 200|
|Ask||117.99 x 200|
|Day's Range||116.97 - 117.92|
|52 Week Range||94.42 - 127.64|
|PE Ratio (TTM)||44.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
These three healthcare stocks might be great buys for savvy investors.
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.